On Wednesday, World Health Organisation (WHO) said it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin and will meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing.

• PM Modi to Seek Ideas for Sustaining Growth Amid Global Uncertainties
• Meta’s Ray-Ban Smart Glasses May Soon Display Notifications on Built-in Screens
• President to Award Pradhan Mantri Rashtriya Bal Puraskar to 17 Children on 26th December
• Akums Drugs Inks a Rs 1,760 Crore CDMO Agreement
• China to Raise Deficit and Increase Spending in 2025

WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure, the WHO tweeted.

The Technical Advisory Group met on October 26 and decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine”.

The Technical Advisory Group expects to receive these clarifications from the manufacturer (Bharat Biotech) by the end of this week. It aims to reconvene for the final risk-benefit assessment on Wednesday, November 3, 2021, the WHO tweeted.